Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2004-02-05
2009-02-10
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S324000, C530S325000, C530S326000
Reexamination Certificate
active
07488481
ABSTRACT:
The present invention is directed to peptides that are capable of blocking the entry of HIV-1 into host cells by means of the CCR5 receptor. The affinity of the peptides for gp120 on the HIV viral surface may be increased by sulfating tyrosine residues. In addition, the invention is directed to a method for increasing the affinity of antibodies for their antigens by sulfating tyrosine residues in the antibody amino acid chain.
REFERENCES:
patent: 2001/0039026 (2001-11-01), Dobbs et al.
patent: 2002/0068813 (2002-06-01), Dragic et al.
Berger, “HIV Entry and Tropism: The Chemokine Receptor Connection,”AIDS 11(Supp. A):S3-S16 (1997).
Cole, et al., “Characterization of Neutralization Epitopes of Simian Immunodeficiency Virus (SIV) Recognized by Rhesus Monoclonal Antibodies Derived from Monkeys Infected with an Attenuated SIV Strain,”Virology 290:59-73 (2001).
Cormier, et al., “Specific Interaction of CCR5 Amino-Terminal Domain Peptides Containing Sulfotyrosines with HIV-1 Envelope Glycoprotein gp120,”Proc. Natl. Acad. Sci. USA 97:5762-5767 (2000).
Deng, et al., “Identification of a Major Co-Receptor for Primary Isolates of HIV-1,”Nature 381:661-666 (1996).
Doranz, et al., “Chemokine Receptors as Fusion Cofactors for Human Immunodeficiency Virus Type 1 (HIV-1),”Immunologic Research 16:15-28 (1997).
Dragic, et al., “HIV-1 Entry into CDR+Cells Is Mediated by the Chemokine Receptor CC-CKR-5,”Nature . 381:667-673 (1996).
Farzan, et al., “A Tyrosine-Rich Region in the N Terminus of CCR5 Is Important for Human Immunodeficiency Virus Type 1 Entry and Mediates an Association between gp120 and CCR5,”J. Virol. 72:1160-1164 (1998).
Farzan, et al., “Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry,”Cell 96:667-676 (1999).
Farzan, et al., “A Tyrosine-Sulfated Peptide Based on the N Terminus of CCR5 Interacts with a CD4-Enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry,”J. Biol. Chem. 275:33516-33521 (2000).
Fouts, et al., “Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates with Antibody Binding to the Oligomeric Form of the Envelope Glycoprotein Complex,”J. Virol. 71:2779-2785 (1997).
Ho, et al., “Conformational Epitope on gp120 Important in CD4 Binding and Human Immunodeficiency Virus Type 1 Neutralization Identified by a Human Monoclonal Antibody,”J. Virol. 65:489-493 (1991).
Farzan, M.;A Tyrosine-sulfated Peptide Based on the N Terminus of CCR5 interacts with a CD4-enhanced Epitope of the HIV-1 gp120 Envelope Glycoprotein and Inhibits HIV-1 Entry.; Oct. 27, 2000, vol. 275, No. 43, pp. 33516-33521.
Dorfman Tatyana K.
Farzan Michael R.
Law Office of Michael A. Sanzo, LLC
Parkin Jeffrey S.
Sanzo Michael A.
The Brigham and Women's Hospital, Inc.
LandOfFree
Polypeptides derived from anti-HIV-1 gp120 antibodies that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides derived from anti-HIV-1 gp120 antibodies that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides derived from anti-HIV-1 gp120 antibodies that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4105775